tiprankstipranks
NeoGenomics backs FY24 revenue view $655M-$667M, consensus $662M
The Fly

NeoGenomics backs FY24 revenue view $655M-$667M, consensus $662M

Backs FY24 adjusted EBITDA view $37M-$40M. The company said, “The Company has reaffirmed its full-year 2024 guidance, originally issued on November 5, 2024. For the year ended December 31, 2024, consolidated revenue is expected to be in the range of $655 to $667 million. Net loss is expected to be in the range of $(81) to $(78) million. Adjusted EBITDA is expected to be in the range of $37 to $40 million.”

Maximize Your Portfolio with Data Driven Insights:

  • Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
  • Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App